Lung Cancer
News
FDA approves pembrolizumab for advanced SCLC
The approval was based on an overall response rate of 19% in two nonrandomized trials.
Conference Coverage
Adding ipilimumab to nivolumab provides no benefit in SCC trial
CHICAGO – There was no difference in overall or progression-free survival between patients receiving ipilimumab plus nivolumab and those receiving...
Conference Coverage
Adjuvant immunotherapy results ‘encouraging’ in early NSCLC
CHICAGO – About one-fifth of patients with resectable non–small cell lung cancer had major pathological responses with atezolizumab monotherapy...
Conference Coverage
Repotrectinib highly active in ROS1-positive lung cancer
Pivotal phase 2 portion of study to commence later this year.
From the Journals
Low-dose CT lung cancer screening nets payoff in community setting too
A survey of 165 lung cancer screening centers suggests low-dose CT screening is being effectively implemented in community practices, replicating...
News
FDA approves NovoTTF-100L System for advanced mesothelioma
The System delivers electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division and can be prescribed only by a...
From the Journals
Antiangiogenics linked to fatal bleeds after RT in patients with “ultracentral” lung tumors
Of six fatal pulmonary hemorrhages, four occurred in patients receiving bevacizumab or pazopanib within 30 days of stereotactic body radiation...
From the Journals
Younger patients with NSCLC tend to live longer
According to a retrospective analysis, younger patients with NSCLC had better survival, despite higher rates of brain metastasis and drive...
Conference Coverage
Circulating tumor cells predict NSCLC survival, but clinical role uncertain
GENEVA - CTC counts of at least 5 cells per 7.5 mL were associated with reduced overall survival in a retrospective analysis involving 550...
Conference Coverage
Afatinib shows safety and efficacy among elderly
GENEVA – In a retrospective analysis of the GIDEON phase 3 trial involving patients with EGFR-positive NSCLC, there...